The use of oncolytic viruses to overcome lung cancer drug resistance

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 629-635

  Beljanski, Vladimir ^a   Hiscott, John ^a  

^a Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; ENTINOSTAT; FLUCYTOSINE; FLUOROURACIL; LONTUCIREV; ONCOLYTIC VIRUS; RAPAMYCIN; TG 4010; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CANCER RESISTANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TRANSGENIC ORGANISM; TUMOR CELL;

EID: 84867395933     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.07.006     Document Type: Review

References (63)

1. D.S. Tan, M. Gerlinger, B.T. Teh, and C. Swanton Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference European Journal of Cancer 46 2010 2166 2177
2. Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A: Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Molecular Medicine 2012, http://dx.doi.org/10.1002/emmm.201101131, in press.
3. B.C. Baguley Multiple drug resistance mechanisms in cancer Molecular Biotechnology 46 2010 308 316
4. M. Shanker, D. Willcutts, J.A. Roth, and R. Ramesh Drug resistance in lung cancer Lung Cancer: Targets and Therapy 1 2010 23 26
5. C.A. Carter, and G. Giaccone Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors Current Opinion in Oncology 24 2012 123 129
6. F. Janku, D.J. Stewart, and R. Kurzrock Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nature Reviews Clinical Oncology 7 2010 401 414
7. N.G. Chen, A.A. Szalay, R.M. Buller, and U.M. Lauer Oncolytic viruses Advances in Virology 2012 2012 320206
8. M. Bauzon, and T.W. Hermiston Oncolytic viruses: the power of directed evolution Advances in Virology 2012 2012 586389
9. R. Auer, and J.C. Bell Oncolytic viruses: smart therapeutics for smart cancers Future Oncology 8 2012 1 4
10. T. Kottke, F. Errington, J. Pulido, F. Galivo, J. Thompson, P. Wongthida, R.M. Diaz, H. Chong, E. Ilett, and J. Chester Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors Nature Medicine 17 2011 854 859
11. P. Wongthida, R.M. Diaz, C. Pulido, D. Rommelfanger, F. Galivo, K. Kaluza, T. Kottke, J. Thompson, A. Melcher, and R. Vile Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus Human Gene Therapy 22 2011 1343 1353
12. R.M. Diaz, F. Galivo, T. Kottke, P. Wongthida, J. Qiao, J. Thompson, M. Valdes, G. Barber, and R.G. Vile Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus Cancer Research 67 2007 2840 2848
13. B.W. Bridle, K.B. Stephenson, J.E. Boudreau, S. Koshy, N. Kazdhan, E. Pullenayegum, J. Brunelliere, J.L. Bramson, B.D. Lichty, and Y. Wan Potentiating cancer immunotherapy using an oncolytic virus Molecular Therapy 18 2010 1430 1439
14. J. Brun, D.J. Mahoney, F.L. Boeuf, C. Lefebvre, C.A. Sanaei, T. Falls, J. Andrea McCart, and D.F. Stojdl Oncolytic vaccinia virus safely and effectively treats skin tumours in mouse models of xeroderma pigmentosum International Journal of Cancer 2012 10.1002/ijc.27695
15. L.S. Young, P.F. Searle, D. Onion, and V. Mautner Viral gene therapy strategies: from basic science to clinical application Journal of Pathology 208 2006 299 318
16. C. Alvarez-Breckenridge, B. Kaur, and E.A. Chiocca Pharmacologic and chemical adjuvants in tumor virotherapy Chemical Reviews 109 2009 3125 3140
17. S.J. Russell, K.W. Peng, and J.C. Bell Oncolytic virotherapy Nature Biotechnology 30 2012 658 670
18. D.J. Mahoney, C. Lefebvre, K. Allan, J. Brun, C.A. Sanaei, S. Baird, N. Pearce, S. Gronberg, B. Wilson, and M. Prakesh Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death Cancer Cell 20 2011 443 456
19. L. Decoster, I. Wauters, and J.F. Vansteenkiste Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development Annals of Oncology 23 2012 1387 1393
20. D.F. Stojdl, B.D. Lichty, B.R. tenOever, J.M. Paterson, A.T. Power, S. Knowles, R. Marius, J. Reynard, L. Poliquin, and H. Atkins VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 4 2003 263 275
21. T. Fukazawa, Y. Maeda, J. Matsuoka, T. Ono, K. Mominoki, T. Yamatsuji, K. Shigemitsu, I. Morita, I. Murakami, and H. Tanaka Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer Anticancer Research 30 2010 4925 4935
22. J.F. Zhang, F. Wei, H.P. Wang, H.M. Li, W. Qiu, P.K. Ren, X.F. Chen, and Q. Huang Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo Journal of Experimental and Clinical Cancer Research 29 2010 52
23. J.Y. Oh, M.Y. Park, D.R. Kim, J.H. Lee, S.H. Shim, J.H. Chung, H.I. Yoon, M.W. Sung, Y.S. Kim, and C.T. Lee Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase International Journal of Molecular Medicine 25 2010 369 376
24. F. Yao, N. Murakami, O. Bleiziffer, P. Zhang, N.V. Akhrameyeva, X. Xu, and R. Brans Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy Journal of Virology 84 2010 8163 8171
25. S. Miyamoto, H. Inoue, T. Nakamura, M. Yamada, C. Sakamoto, Y. Urata, T. Okazaki, T. Marumoto, A. Takahashi, and K. Takayama Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma Cancer Research 72 2012 2609 2621
26. S. Meng, Z. Zhou, F. Chen, X. Kong, H. Liu, K. Jiang, W. Liu, M. Hu, X. Zhang, and C. Ding Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo Cancer Letters 317 2012 56 64
27. C.M. Rudin, J.T. Poirier, N.N. Senzer, J. Stephenson Jr., D. Loesch, K.D. Burroughs, P.S. Reddy, C.L. Hann, and P.L. Hallenbeck Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features Clinical Cancer Research 17 2011 888 895
28. S.A. Gujar, P. Marcato, D. Pan, and P.W. Lee Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity Molecular Cancer Therapeutics 9 2010 2924 2933
29. S. Sei, J.K. Mussio, Q.E. Yang, K. Nagashima, R.E. Parchment, M.C. Coffey, R.H. Shoemaker, and J.E. Tomaszewski Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells Molecular Cancer 8 2009 47 62
30. R. Dreicer, W.M. Stadler, F.R. Ahmann, T. Whiteside, N. Bizouarne, B. Acres, J.M. Limacher, P. Squiban, and A. Pantuck MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure Investigational New Drugs 27 2009 379 386
31. E. Quoix, R. Ramlau, V. Westeel, Z. Papai, A. Madroszyk, A. Riviere, P. Koralewski, J.L. Breton, E. Stoelben, and D. Braun Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial Lancet Oncology 12 2011 1125 1133
32. T.L. Nguyen, M.G. Wilson, and J. Hiscott Oncolytic viruses and histone deacetylase inhibitors - a multi-pronged strategy to target tumor cells Cytokine and Growth Factor Reviews 21 2010 153 159
33. T. Alain, X. Lun, Y. Martineau, P. Sean, B. Pulendran, E. Petroulakis, F.J. Zemp, C.G. Lemay, D. Roy, and J.C. Bell Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production Proceedings of the National Academy of Sciences of the United States of America 107 2010 1576 1581
34. G. Fulci, L. Breymann, D. Gianni, K. Kurozomi, S.S. Rhee, J. Yu, B. Kaur, D.N. Louis, R. Weissleder, and M.A. Caligiuri Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses Proceedings of the National Academy of Sciences of the United States of America 103 2006 12873 12878
35. J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R.M. Diaz, J. Thompson, P. Selby, J. de Bono, and A. Melcher Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus Clinical Cancer Research 14 2008 259 269
36. D. Wodarz Use of oncolytic viruses for the eradication of drug-resistant cancer cells Journal of the Royal Society Interface 6 2009 179 186
37. B.D. Lichty, A.T. Power, D.F. Stojdl, and J.C. Bell Vesicular stomatitis virus: re-inventing the bullet Trends in Molecular Medicine 10 2004 210 216
38. M. Fernandez, M. Porosnicu, D. Markovic, and G.N. Barber Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease Journal of Virology 76 2002 895 904
39. N.D. Lawson, E.A. Stillman, M.A. Whitt, and J.K. Rose Recombinant vesicular stomatitis viruses from DNA Proceedings of the National Academy of Sciences of the United States of America 92 1995 4477 4481
40. S. Balachandran, M. Porosnicu, and G.N. Barber Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis Journal of Virology 75 2001 3474 3479
41. D.R. Kim, M.Y. Park, H.J. Lim, J.S. Park, Y.J. Cho, S.W. Lee, H.I. Yoon, J.H. Lee, Y.S. Kim, and C.T. Lee Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors International Journal of Molecular Medicine 29 2012 218 224
42. A. Otsuki, A. Patel, K. Kasai, M. Suzuki, K. Kurozumi, E.A. Chiocca, and Y. Saeki Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses Molecular Therapy 16 2008 1546 1555
43. T.L. Nguyen, H. Abdelbary, M. Arguello, C. Breitbach, S. Leveille, J.S. Diallo, A. Yasmeen, T.A. Bismar, D. Kirn, and T. Falls Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis Proceedings of the National Academy of Sciences of the United States of America 105 2008 14981 14986
44. N. De Silva, H. Atkins, D.H. Kirn, J.C. Bell, and C.J. Breitbach Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses Cytokine and Growth Factor Reviews 21 2010 135 141
45. C.M. Sorenson Bcl-2 family members and disease Biochimica et Biophysica Acta 1644 2004 169 177
46. R. Cesaire, S. Oliere, E. Sharif-Askari, M. Loignon, A. Lezin, S. Olindo, G. Panelatti, M. Kazanji, R. Aloyz, and L. Panasci Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia Oncogene 25 2006 349 358
47. J.C. Reed Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities Cell Death and Differentiation 13 2006 1378 1386
48. S. Samuel, V.F. Tumilasci, S. Oliere, T.L. Nguyen, A. Shamy, J. Bell, and J. Hiscott VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia Molecular Therapy 18 2010 2094 2103
49. V.F. Tumilasci, S. Oliere, T.L. Nguyen, A. Shamy, J. Bell, and J. Hiscott Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis Journal of Virology 82 2008 8487 8499
50. A. Neschadim, J.C. Wang, A. Lavie, and J.A. Medin Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer Cancer Gene Therapy 19 2012 320 327
51. M. Porosnicu, A. Mian, and G.N. Barber The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene Cancer Research 63 2003 8366 8376
52. A. Goel, S.K. Carlson, K.L. Classic, S. Greiner, S. Naik, A.T. Power, J.C. Bell, and S.J. Russell Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene Blood 110 2007 2342 2350
53. S. Leveille, S. Samuel, M.L. Goulet, and J. Hiscott Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy Cancer Gene Therapy 18 2011 435 443
54. R. Hernandez-Alcoceba Recent advances in oncolytic virus design Clinical and Translational Oncology 13 2011 229 239
55. P.S. Adusumilli, B.M. Stiles, M.K. Chan, T.C. Chou, R.J. Wong, V.W. Rusch, and Y. Fong Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer Annals of Thoracic Surgery 80 2005 409 416
56. Y. Touchefeu, G. Vassaux, and K.J. Harrington Oncolytic viruses in radiation oncology Radiotherapy and Oncology 99 2011 262 270
57. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D.D. Von Hoff, and D.H. Kirn ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nature Medicine 3 1997 639 645
58. L. You, C.T. Yang, and D.M. Jablons ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients Cancer Research 60 2000 1009 1013
59. Y. Cai, X. Liu, W. Huang, K. Zhang, and X.Y. Liu Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy Acta Biochimica et Biophysica Sinica (Shanghai) 44 2012 535 543
60. S. Zhong, D. Yu, Y. Wang, S. Qiu, S. Wu, and X.Y. Liu An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer Acta Oncologica 49 2010 91 99
61. L.A. Norian, T.P. Kresowik, H.M. Rosevear, B.R. James, T.R. Rosean, A.J. Lightfoot, T.A. Kucaba, C. Schwarz, C.J. Weydert, and M.D. Henry Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy PLoS ONE 7 2012 e31085
62. A. Bateman, F. Bullough, S. Murphy, L. Emiliusen, D. Lavillette, F.L. Cosset, R. Cattaneo, S.J. Russell, and R.G. Vile Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth Cancer Research 60 2000 1492 1497
63. G.R. Simpson, Z. Han, B. Liu, Y. Wang, G. Campbell, and R.S. Coffin Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control Cancer Research 66 2006 4835 4842